Professor Klaus Okkenhaug
Position: Professor
Personal home page:
https://www.path.cam.ac.uk/directory/klaus-okkenhaug
PubMed journal articles - click here
Professor Klaus Okkenhaug is pleased to consider applications from prospective PhD students.
Phosphoinositide 3-kinases (PI3Ks) are enzymes that act downstream of tyrosine kinase signalling and generate second messenger signalling molecules that can regulate cell survival, metabolism, growth, proliferation, differentiation and migration. We are investigating the regulation of PI3Ks in lymphocytes using genetic and pharmacological approaches. We also investigate how manipulation of PI3K signalling influences different kinds of immune responses including against cancer. Results from these investigations help provide rationale for the use of PI3K inhibitors in therapeutic settings. Indeed, the PI3Kdelta inhibitor idelalisib is already approved for the treatment of certain B cell malignancies (CLL, SLL, FL) and PI3Kdelta inhibitors are also being trialled as immunotherapeutic agents in solid cancer.
Symplectic Elements feed provided by Research Information, University of Cambridge
PI3K inhibitors are finally coming of age
Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K.
Nat Rev Drug Discov. 2021. 14. https://doi.org/10.1038/s41573-021-00209-1
Full text available here: https://rdcu.be/cmDLM
Phosphoinositide 3‐kinase δ is a regulatory T‐cell target in cancer immunotherapy
EL Lim, K Okkenhaug
Immunology. 2019. 157 (3), 210-218.
DOI: https://doi.org/10.1111/imm.13082
Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors
Lim EL, Cugliandolo FM, Rosner DR, Gyori D, Roychoudhuri R, Okkenhaug K.
JCI Insight. 2018. 3(11). pii: 120626.
DOI: https://doi.org/10.1172/jci.insight.120626
Okkenhaug K, Graupera M, Vanhaesebroeck B.
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Cancer Discov. 2016 O6(10):1090-1105.
DOI: https://doi.org/10.1158/2159-8290.cd-16-0716
Ali K et al. 2014.
Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer.
Nature 510: 407-11
DOI: https://doi.org/10.1038/nature13444
Burger JA, Okkenhaug K. 2014.
Haematological cancer: idelalisib-targeting PI3Kdelta in patients with B-cell malignancies.
Nat Rev Clin Oncol 11: 184-6
DOI: https://doi.org/10.1038/nrclinonc.2014.42
Okkenhaug K. 2013.
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells.
Annual Review of Immunology 31: 675-704
https://doi.org/10.1146/annurev-immunol-032712-095946
